Timothy P. Fleming

Timothy P. Fleming

Auto-generated profile, based on publicly available information

Timothy P. Fleming

Norton Thoracic Institute, St. Joseph Hospital and Medical Center, Phoenix, AZ, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2021 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
SBSandhya Bansal
Sandhya Bansal
SPSudhir Perincheri
Sudhir Perincheri
TFTimothy Fleming
Timothy Fleming
CPChristin Poulson
Christin Poulson
BTBrian Tiffany
Brian Tiffany
TMThalachallour Mohanakumar
Thalachallour Mohanakumar
Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) causes severe acute respiratory syndrome. mRNA vaccines directed at the SARS-CoV-2 spike protein resulted in development of Abs and protective immunity. To determine the mechanism, we analyzed the kinetics of induction of circulating exosomes with SARS-CoV-2 spike protein and Ab following vaccination of healthy individuals. Results demonstrated induction of circulating exosomes expressing spike protein on day 14 after vaccination followed by Abs 14 d after the second dose. Exosomes with spike protein, Abs to SARS-CoV-2 spike, and T cells secreting IFN-γ and TNF-α increased following the booster dose. Transmission electron microscopy of exosomes also demonstrated spike protein Ags on their surface. Exosomes with spike protein and Abs decreased in parallel after four months. These results demonstrate an important role of circulating exosomes with spike protein for effective immunization following mRNA-based vaccination. This is further documented by induction of humoral and cellular immune responses in mice immunized with exosomes carrying spike protein.

1 February 2015 in Fertility and Sterility
Verified
Journal Article
Closed access
EHEllen J. Hoekman
Ellen J. Hoekman
VSVincent T.H.B.M. Smit
Vincent T.H.B.M. Smit
TFTimothy P. Fleming
Timothy P. Fleming
LLLeonie A. Louwe
Leonie A. Louwe
GFGert Jan Fleuren
Gert Jan Fleuren
CHCarina G.J.M. Hilders
Carina G.J.M. Hilders

28 November 2024 in Human Immunology
Verified
Journal Article
Closed access
RRRanjithkumar Ravichandran
Ranjithkumar Ravichandran
MRMohammad Rahman
Mohammad Rahman
SBSandhya Bansal
Sandhya Bansal
DSDavide Scozzi
Davide Scozzi
TFTimothy Fleming
Timothy Fleming
TMThalachallour Mohanakumar
Thalachallour Mohanakumar

6 February 2026 in Cancer Immunology Research
Verified
Journal Article
Closed access
RMRashmi Mishra
Rashmi Mishra
FAFoluso Ademuyiwa
Foluso Ademuyiwa
YYYilin Yang
Yilin Yang
JHJohn Herndon
John Herndon
LLLijin Li
Lijin Li
WGWilliam E. Gillanders
William E. Gillanders
Tumor-associated antigen (TAA) vaccines are being explored as a strategy to induce antitumor immune responses. Mammaglobin-A (Mam-A) is a TAA expressed in >50% of patients with breast cancer. Previously, we have shown that Mam-A DNA vaccines induce antitumor immune responses in patients with stable metastatic disease. To further evaluate the potential of the Mam-A vaccine, we initiated a phase Ib clinical trial in patients with estrogen receptor–positive breast cancer prior to surgery. Eight patients were assigned to arm 1 (neoadjuvant endocrine therapy alone) and 17 to arm 2 (neoadjuvant endocrine therapy plus Mam-A vaccination); the final analysis included 8 patients from arm 1 and 13 from arm 2. Ex vivo enzyme-linked immunospot (ELISpot) analysis of peripheral blood mononuclear cells demonstrated that Mam-A vaccination induced Mam-A–specific T cells in 8 of 13 patients. Intracellular cytokine staining and Mam-A–specific tetramer staining revealed that vaccine-induced Mam-A–specific T cells included both CD4+ and CD8+ polyfunctional T cells. Finally, high-throughput imaging mass cytometry identified 24 cellular metaclusters with features of tumor, immune, stromal, and endothelial cells and revealed an increased CD8+ T-cell prevalence in the tumor after Mam-A vaccination. In particular, vaccination was associated with the infiltration of PD-1+CD8+ T cells. In addition, postvaccination tumor samples exhibited close spatial interactions between cytotoxic CD8+ T cells (CTL) and Mam-A+ tumor cells and between CTL and antigen-experienced CD4+ T cells. Together, these results suggest that Mam-A DNA vaccination elicits both systemic and intratumoral antitumor immune responses.

1 June 2021 in OncoTargets and Therapy
Verified
Journal Article
Open access
PDF file
JLJohn Lee
John Lee
RCRongbing Chen
Rongbing Chen
TMT Mohanakumar
T Mohanakumar
RBRoss Bremner
Ross Bremner
SMSumeet Mittal
Sumeet Mittal
TFTimothy P Fleming
Timothy P Fleming
Introduction: Esophageal cancer (EC) is an aggressive cancer type that is increasing at a high rate in the US and worldwide. Extensive sequencing of EC specimens has shown that there are no consistent driver mutations that can impact treatment strategies. The goal of this study was to identify activated tyrosine kinase receptors (TKRs) in EC samples as potential targets in the treatment of EC. Methods: Activated tyrosine kinase receptors were detected using a dot-blot array for human TK receptors. Human esophageal cancer cell lines were transplanted into immunocompromised mice, and tumor xenografts were subjected to tyrosine kinase inhibitors based on the dot-blot array data. Results: Using the OE33 esophageal cancer cell line, we identified activated EGF receptor (EGFR), as well as ErbB2 and ErbB3. Treatment of this cell line with erlotinib, a specific inhibitor of EGFR, did not impact the growth of this tumor cell line. Treating the OE33 cell line with afatinib, a pan-EGFR family inhibitor resulted in the growth inhibition of OE33, indicating that the ErbB2 and ErbB3 receptors were contributing to tumor cell proliferation. Afatinib treatment of mice growing OE33 tumors inhibited growth of the OE33 tumor cells. Discussion: Activated tyrosine kinase receptors were readily detected in both cancer cell lines and human esophageal cancer samples. By identifying the activated receptors and then using the appropriate tyrosine kinase inhibitors, we can block tumor growth in vitro and in animal xenografts. We propose that identifying and targeting activated TKRs can be used as a personalized EC tumor treatment strategy.

4 September 2026 in Science Advances
Verified
Journal Article
Closed access
FPFelicia Zhang Perkins
Felicia Zhang Perkins
XZXiuli Zhang
Xiuli Zhang
YYYik Yeung Lawrence Yu
Yik Yeung Lawrence Yu
YYYilin Yang
Yilin Yang
DCDarren Cullinan
Darren Cullinan
WGWilliam E. Gillanders
William E. Gillanders
Pancreatic ductal adenocarcinoma (PDAC) is unresponsive to standard immunotherapies despite harboring cancer neoantigens capable of eliciting T cell responses. We completed two phase 1 clinical trials (NCT03956056 and NCT03122106) evaluating safety and immunogenicity of synthetic long peptide (SLP) and DNA personalized cancer vaccines (PCVs). PCVs were administered after resection and adjuvant chemotherapy. Tumor/normal whole-exome sequencing, RNA sequencing, and pVACtools were used to identify and prioritize candidate PCV neoantigens. PCVs were well tolerated without any grade ≥3 adverse events. Neoantigen-specific responses were demonstrated by interferon-γ enzyme-linked immunospot and intracellular cytokine staining. Expanded T cell receptor clonotypes were sequenced and transduced into autologous peripheral blood mononuclear cells to confirm neoantigen specificity. When compared with a contemporaneous institutional propensity-matched cohort, PCV patients demonstrated a trend toward prolonged median overall survival (4.4 versus 3.5 years, log-rank P = 0.23). Overall, PDAC PCVs are safe and feasible and elicit polyclonal T cell responses, linking prioritized cancer neoantigens to functional antitumor immunity.